PE20020207A1 - Preparaciones de liberacion controlada que comprenden derivados de quinolona y polimeros - Google Patents

Preparaciones de liberacion controlada que comprenden derivados de quinolona y polimeros

Info

Publication number
PE20020207A1
PE20020207A1 PE2001000618A PE2001000618A PE20020207A1 PE 20020207 A1 PE20020207 A1 PE 20020207A1 PE 2001000618 A PE2001000618 A PE 2001000618A PE 2001000618 A PE2001000618 A PE 2001000618A PE 20020207 A1 PE20020207 A1 PE 20020207A1
Authority
PE
Peru
Prior art keywords
mixed
agent
ciprofloxacin
viscosity
refers
Prior art date
Application number
PE2001000618A
Other languages
English (en)
Inventor
Roland Rupp
Venkata-Rangarao Kanikanti
Wolfgang Weber
Peter Deuringer
Jan-Olav Henck
Heino STAB
Takaaki Nishioka
Yoshifumi Katakawa
Chika Taniguchi
Hitoshi Ichihashi
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20020207A1 publication Critical patent/PE20020207A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN POLIMERO FORMADOR DE GEL CON UNA VISCOSIDAD DE 5 cP A 400 cP TAL COMO HIDROXIPROPILMETILCELULOSA CON UNA VISCOSIDAD DE 75cP COMO MAXIMO MEDIDA EN FORMA DE UNA SOLUCION ACUOSA AL 2% EN PESO A 20°C DE TEMPERATURA Y b) UNA MEZCLA DE DOS DERIVADOS DE QUINOLONA TAL COMO CIPROFLOXACINA Y CIPROFLOXACINA-BETAINA. LA MATRIZ ANTIBIOTICA QUE CONTIENE 80% DE QUINOLONA Y SE LIBERA TANTO EN ACIDO CLORHIDRICO 0,1 N COMO EN TAMPON ACETATO A pH 4,5 EN EL ENSAYO PALA USP-XXIV A 50 REVOLUCIONES POR MIN/37°C DURANTE 1-4 HORAS. LAMATRIZ CONTIENE UNA PARTE DE LIBERACION RAPIDA (IR) Y OTRA DE RETARDO (CR). SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE: MEZCLAR LA SUSTANCIA ACTIVA CON UN AGENTE DISGREGANTE, SE GRANULA Y SE MEZCLA CON UN AGENTE DESLIZANTE Y LUBRICANTE (IR), SE MEZLA OTRA PARTE DE LA SUSTANCIA ACTIVA CON ACIDO E HIDROXIPROPILMETILCELULOSA, SE GRANULA Y SE MEZCLA CON UN AGENTE DESLIZANTE Y LUBRICANTE (CR) , FINALMENTE SE COMPRIMEN Y SE RECUBREN AMBAS PARTES
PE2001000618A 2000-06-26 2001-06-26 Preparaciones de liberacion controlada que comprenden derivados de quinolona y polimeros PE20020207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10031043A DE10031043A1 (de) 2000-06-26 2000-06-26 Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
PE20020207A1 true PE20020207A1 (es) 2002-04-27

Family

ID=7646816

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000618A PE20020207A1 (es) 2000-06-26 2001-06-26 Preparaciones de liberacion controlada que comprenden derivados de quinolona y polimeros

Country Status (41)

Country Link
US (3) US7709022B2 (es)
EP (1) EP1296685B1 (es)
JP (1) JP4958373B2 (es)
KR (1) KR100939617B1 (es)
CN (1) CN1273138C (es)
AR (1) AR029688A1 (es)
AT (1) ATE355062T1 (es)
AU (1) AU2001270573A1 (es)
BG (1) BG65914B1 (es)
BR (1) BRPI0111911B8 (es)
CA (1) CA2414271C (es)
CU (1) CU23264B7 (es)
CY (1) CY1107574T1 (es)
CZ (1) CZ301812B6 (es)
DE (2) DE10031043A1 (es)
DK (1) DK1296685T3 (es)
DO (1) DOP2001000199A (es)
EE (1) EE04992B1 (es)
ES (1) ES2282270T3 (es)
GT (1) GT200100126A (es)
HK (1) HK1058479A1 (es)
HN (1) HN2001000132A (es)
HR (1) HRP20030050B1 (es)
HU (1) HU229806B1 (es)
IL (2) IL153333A0 (es)
MA (1) MA25761A1 (es)
MX (1) MXPA02012727A (es)
MY (1) MY140994A (es)
NO (1) NO325415B1 (es)
NZ (1) NZ523352A (es)
PE (1) PE20020207A1 (es)
PL (1) PL203710B1 (es)
PT (1) PT1296685E (es)
RU (1) RU2332204C2 (es)
SI (1) SI1296685T1 (es)
SK (1) SK287384B6 (es)
SV (1) SV2002000505A (es)
TW (1) TWI279232B (es)
UA (1) UA83616C2 (es)
WO (1) WO2002000219A1 (es)
ZA (1) ZA200210350B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
WO2004000924A1 (en) * 2002-06-25 2003-12-31 Micro Science Tech Co., Ltd. Polymer resin formulation having anti-microbial or anti-cogulability and preparation method thereof
BRPI0407368A (pt) * 2003-02-10 2006-02-14 Bayer Healthcare Ag tratamento de doenças bacterianas dos órgãos respiratórios mediante aplicação local e fluor-quinolonas.
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
KR100974482B1 (ko) 2003-03-27 2010-08-10 가부시키가이샤 바이오악티스 비강용 분말 약제 투약 장치
CA2532714C (en) 2003-08-04 2010-11-16 Kyorin Pharmaceutical Co., Ltd. Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
US20080206329A1 (en) * 2004-12-03 2008-08-28 Sanjay Verma Modified Release Ciprofloxacin Compositions
DK1868581T3 (da) * 2005-04-11 2012-07-09 Abbott Lab Farmaceutiske sammensætninger med forbedrede opløsningsprofiler til dårligt opløselige lægemidler
DE602006012962D1 (de) * 2006-07-19 2010-04-29 Tabuk Pharmaceutical Mfg Co Pharmazeutische Zubereitungen von Ciprofloxacin
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
WO2009117130A2 (en) * 2008-03-21 2009-09-24 Mylan Pharmaceuticals, Inc. Extended release forumulation containing a wax
BRPI1007945C8 (pt) * 2009-02-13 2021-05-25 Romark Laboratories Lc formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US11033624B2 (en) * 2010-06-02 2021-06-15 Novaflux Inc. Medical item for prevention and treatment of ear infection
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
US10285865B2 (en) 2014-05-02 2019-05-14 Novaflux Inc. Drug-releasing device usable in mucosal body cavities
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
FR2100858B1 (es) 1970-07-03 1975-06-06 Daiichi Seiyaku Co
US4122157A (en) 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3142854A1 (de) 1981-10-29 1983-05-11 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-piperazino-chinolin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4530928A (en) * 1982-01-13 1985-07-23 Merck & Co., Inc. Quinoline carboxylic acid complexes with guanidinium carbonate
US4440740A (en) * 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
IT1198386B (it) 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
IL70071A (en) 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US5286754A (en) * 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
ATE71293T1 (de) 1986-09-18 1992-01-15 London Pharmacy Innovation Arzneiformulierung.
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
JP2958731B2 (ja) * 1992-02-14 1999-10-06 日本特殊陶業株式会社 酸化アルミニウム基焼結体及びその製造方法
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
JP2686215B2 (ja) 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
CN1048628C (zh) 1995-07-06 2000-01-26 东北制药总厂 环丙沙星注射液的制备方法
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
IN186245B (es) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
PL192273B1 (pl) * 1997-09-25 2006-09-29 Bayer Ag Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
SK285478B6 (sk) 1998-09-14 2007-02-01 Ranbaxy Laboratories Limited Jednodenná formulácia na orálne podanie na kontrolované uvoľňovanie ciprofloxacínu
MXPA02004413A (es) 1999-11-02 2002-09-02 Depomed Inc Induccion farmacologica del modo de alimentacion, para la administracion aumentada de drogas al estomago.
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6780057B2 (en) * 2001-12-21 2004-08-24 Intel Corporation Coaxial dual pin sockets for high speed I/O applications

Also Published As

Publication number Publication date
SV2002000505A (es) 2002-12-02
CA2414271C (en) 2005-09-27
HRP20030050A2 (en) 2004-06-30
SK287384B6 (sk) 2010-08-09
BR0111911A (pt) 2003-05-13
US20040024018A1 (en) 2004-02-05
BRPI0111911B8 (pt) 2021-05-25
GT200100126A (es) 2002-01-31
CA2414271A1 (en) 2002-12-23
DK1296685T3 (da) 2007-05-07
SI1296685T1 (sl) 2007-06-30
BG65914B1 (bg) 2010-05-31
SK18212002A3 (sk) 2003-04-01
KR20030023883A (ko) 2003-03-20
CU23264B7 (es) 2008-03-14
AU2001270573A1 (en) 2002-01-08
DOP2001000199A (es) 2002-05-15
BG107372A (bg) 2003-09-30
EP1296685A1 (de) 2003-04-02
KR100939617B1 (ko) 2010-02-01
NO20026160D0 (no) 2002-12-20
ATE355062T1 (de) 2006-03-15
EE200200707A (et) 2004-08-16
CZ301812B6 (cs) 2010-06-30
HUP0300953A3 (en) 2009-04-28
CN1438889A (zh) 2003-08-27
HN2001000132A (es) 2001-09-11
PL203710B1 (pl) 2009-11-30
JP2004504278A (ja) 2004-02-12
NO325415B1 (no) 2008-04-21
WO2002000219A1 (de) 2002-01-03
ZA200210350B (en) 2004-02-10
DE50112123D1 (de) 2007-04-12
US8187632B2 (en) 2012-05-29
DE10031043A1 (de) 2002-02-14
IL153333A0 (en) 2003-07-06
CY1107574T1 (el) 2013-03-13
EP1296685B1 (de) 2007-02-28
MXPA02012727A (es) 2003-05-14
US7780986B2 (en) 2010-08-24
BRPI0111911B1 (pt) 2015-08-25
IL153333A (en) 2010-05-31
HRP20030050B1 (en) 2011-07-31
MA25761A1 (fr) 2003-04-01
EE04992B1 (et) 2008-04-15
US20070065509A1 (en) 2007-03-22
HK1058479A1 (en) 2004-05-21
JP4958373B2 (ja) 2012-06-20
TWI279232B (en) 2007-04-21
US7709022B2 (en) 2010-05-04
MY140994A (en) 2010-02-12
NO20026160L (no) 2002-12-20
CZ20024216A3 (cs) 2003-04-16
NZ523352A (en) 2004-08-27
RU2332204C2 (ru) 2008-08-27
AR029688A1 (es) 2003-07-10
PT1296685E (pt) 2007-05-31
UA83616C2 (uk) 2008-08-11
HU229806B1 (en) 2014-07-28
PL360632A1 (en) 2004-09-20
CN1273138C (zh) 2006-09-06
US20070237824A1 (en) 2007-10-11
HUP0300953A2 (hu) 2003-08-28
ES2282270T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
PE20020207A1 (es) Preparaciones de liberacion controlada que comprenden derivados de quinolona y polimeros
ES2277340T3 (es) Formulacion de liberacion continua que contiene tres tipos diferentes de polimeros.
US6103266A (en) Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
AU2011234492B2 (en) Thermogelling anaesthetic compositions
EP1079813B1 (en) Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US4867970A (en) Moistureless oral drug delivery formulation and method for preparing same
AU742301B2 (en) Sustained release formulation containing three different types of polymers and tablet formed therefrom
RU2142273C1 (ru) Гель для лечения кожных заболеваний и для дезинфекции кожи
EP1110541B1 (en) Controlled release composition comprising a sustained release layer and a fast release layer
AU2022202925A1 (en) Thermosensitive hydrogel collagenase formulations
BR0006246A (pt) Método de preparar uma pelìcula solúvel em água
BRPI0409336A (pt) sistema de liberação compreendendo uma pelìcula de gel termorreversìvel, homogênea, pelìcula de sistema de liberação, e, processo para preparar o sistema de liberação da mesma
JP2018528962A (ja) 熱感受性ヒドロゲルコラゲナーゼ製剤
BR9913696A (pt) Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial
RU2003102365A (ru) Композиции на основе антибиотика хонолона пролонгированного действия и способ их получения
MX2007015783A (es) Tableta que contiene un ingrediente dificilmente soluble.
JP2541573B2 (ja) 徐放性口腔用製剤
HRP20020181B1 (hr) Farmaceutski pripravci koji sadrže derivat benzamida kao aktivan sastojak
KR20010075053A (ko) 국소 투여용 의약 조성물
JPH07223938A (ja) 貼付剤基剤
US20200254011A1 (en) Nanocomposite formulation for use in hemostasis
CA1313620C (en) Oral drug delivery systems
Goudanavar Formulation and evaluation of in-situ gel containing linezolid in the treatment of periodontitis
JO2572B1 (en) A general formula for controlled release
DE60319982D1 (de) Universelle Zusammensetzung zur kontrollierten Wirkstofffreigabe enthaltend Xanthangummi und Natriumalginat

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration